Get started
H. LUNDBECK A/S AHH

H. LUNDBECK A/S A

32.85DKKD
+0.35+1.08%
At close at 15:59 GMT
DKK
No trades
See on Supercharts
Overview
Financials
News Discussions Technicals Seasonals Bonds

HLUN_A fundamentals

Key facts

Market capitalization‪31.45 B‬DKK
Dividend yield (indicated)2.92%
Price to earnings Ratio (TTM)10.26
Basic EPS (TTM)3.17DKK
Founded1950
Employees (FY)‪5.71 K‬
CEOCharl van Zyl
Websitelundbeck.com
About

H. Lundbeck A/S engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders. Its product portfolio targets the following diseases: Alzheimer's, depression, Parkinson's, Schizophrenia, alcohol dependence, anxiety, bipolar disorder, epilepsy, and Huntington's. It operates through the following geographical segments: Europe, United States, and International Markets. The company was founded by Hans Lundbeck on August 14, 1915 and is headquartered in Valby, Denmark.

Ownership
‪‪198.80 M‬‬
Closely held shares
‪‪159.04 M‬‬ (80%)
Free Float shares
‪‪39.76 M‬‬ (20%)
Closely held shares
‪‪159.04 M‬‬ (80%)
Free Float shares
‪‪39.76 M‬‬ (20%)
Capital structure
Market cap
‪‪31.45 B‬‬
Debt
‪‪16.95 B‬‬
Cash & equivalents
‪‪4.66 B‬‬
Enterprise value
‪‪43.74 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪31.45 B‬‬
Price to earning ratio (P/E)
10.26x
Price to sales ratio (P/S)
1.46x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
10.26x
Price to sales ratio (P/S)
1.46x
Valuation ratios
‪0.00‬
‪0.50‬
‪1.00‬
‪1.50‬
‪2.00‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪4.00‬
‪8.00‬
‪12.00‬
‪16.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪2.5%‬
‪7.0%‬
‪11.5%‬
‪16.0%‬
‪20.5%‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪‪1.50 B‬‬
‪‪3.00 B‬‬
‪‪4.50 B‬‬
‪‪6.00 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪1.50 B‬‬
‪‪3.00 B‬‬
‪‪4.50 B‬‬
‪‪6.00 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪1.50 B‬‬
‪‪3.00 B‬‬
‪‪4.50 B‬‬
‪‪6.00 B‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Rexulti
Brintellix/Trintellix
Abilify Long-acting Injectable Franchise
Other Pharmaceuticals
Vyepti
Cipralex/Lexapro
Reconciling Items
By country
Period: 2024
United States
International
Europe
Reconciling Items
Denmark

Dividends

Dividend yield, history and sustainability

Dividend summary
29.98%
Earnings retained
Payout ratio (TTM)
Dividend yield TTM
2.15%
Next payment
0.95
Next ex-date
Mar 27, 2025
Dividend history
‪2.00%‬
‪2.22%‬
‪2.44%‬
‪2.66%‬
‪2.88%‬
2020
2021
2022
2023
2024
‪0.00‬
‪0.25‬
‪0.50‬
‪0.75‬
‪1.00‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪‪−6.00 B‬‬
‪0.00‬
‪‪6.00 B‬‬
‪‪12.00 B‬‬
‪‪18.00 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪12.00 B‬‬
‪‪24.00 B‬‬
‪‪36.00 B‬‬
‪‪48.00 B‬‬
Assets
Liabilities